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Introduction
By most estimates, about one billion
people worldwide are affected by neglect-
ed tropical diseases (NTDs). These diseas-
es are found primarily in developing
countries, and those affected are generally
marginalized sectors of the population that
may not have access to safe water, good
hygiene, or adequate medicines. NTDs
cause major health problems, and often
lead to permanent disability of the victims.
Consequently, the social and economic
impact of these diseases is massive [1].
With the growing recognition of the
deleterious effects of the NTDs, several
initiatives are now underway at national
and international levels to tackle the
problem with the aim of controlling or
eliminating them. The drive to contain or
eliminate the diseases has further been
highlighted in numerous papers [1–10],
through persistent advocacy of the World
Health Organization (WHO) and other
institutions [11–13], and by funding from
government, private, and corporate
grants.
An approach that has received wide
acceptance in recent years is an integrated
strategy that involves mass administration
of combination treatments [4,9–15]. This
is particularly the case when two or more
of the NTDs share a common method of
management. The initial emphasis of this
approach has been on the seven NTDs:
the three soil-transmitted helminthiases
(caused by whipworm, hookworm, and
roundworm), schistosomiasis, lymphatic
filariasis (LF), trachoma, and onchocerci-
asis. The integrated approach typically
involves coordinated use of therapy ac-
cording to established guidelines, leverag-
ing disease-control activities within the
national health system, and active involve-
ment of the community. When the
strategy comprises mass drug administra-
tion (MDA), the whole endemic popula-
tion is normally targeted for treatment.
Given the proven efficacy of the indi-
vidual drugs, an essential facet of the
integrated programs is assessment of the
safety of the combination therapy in
the target population. Accordingly, there
is a growing list of studies that have been
conducted to evaluate the safety of co-
administration of drugs [16–19].
Although there is an obvious apprecia-
tion of the need to conduct studies to
establish the safety of combination drugs
in MDA, there has been no public
discussion on what guidance may be
needed to help researchers in these
resource-constrained areas to design, con-
duct, and analyze such studies. The
objective of this policy platform is, there-
fore, to initiate discussion on this topic,
with particular reference to data handling,
safety assessment, and other aspects of
pharmacovigilance that should be consid-
ered to protect the well-being of the target
population. Examples will be provided
from two studies. The first study [16]
was performed in Zanzibar (the ‘‘Zanzibar
study’’) and examined co-administration of
ivermectin, albendazole, and praziquantel
in children and adults. The second
illustrative study pertains to a triple co-
administration of azithromycin, ivermec-
tin, and albendazole for the treatment of
trachoma and LF (the ‘‘trachoma/LF
study’’). At the time of preparation of this
manuscript, preliminary pharmacokinetic
(PK) studies for the latter have been
reported [15,17].
While the scope of the this policy
platform is the conduct and reporting of
MDA studies, it may be worthwhile to
note the main features that distinguish
such studies from conventional clinical
trials for efficacy. In the last section, some
relevant aspects of the two types are
discussed, with emphasis on compliance
requirements and subject inclusion and
exclusion criteria.
Characterizing Potential
Pharmacokinetic Interactions
In studying the safety of combination
therapy in an MDA setting, it is essential
to establish whether interactions among
the drugs under study alter the PK profiles
of the component agents. Although pre-
dictions can be made about the likelihood
of metabolic or transporter interactions,
such predictions may be difficult when
more than two drugs are given, or for
older drugs that may lack metabolism or
transporter data. A conventional approach
to obtaining reliable PK data involves use
of carefully designed studies in healthy
volunteers. Given the limited availability
of centers capable of running PK studies
and/or assays in countries with high
incidences of NTDs, these may have to
be performed elsewhere. When the con-
duct of such PK studies is impractical,
relevant information may be gathered
through literature review or simulation
and modeling exercises.
For the Zanzibar study [16], PK data in
non-infected subjects indicated the ab-
sence of pharmacologic interactions
among the treatments under consider-
ation, and there was no indication that
triple co-administration would enhance
their toxicity [19]. Preliminary PK inter-
action assessment for a trachoma/LF
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dicting interactions when multiple drugs
are co-administered. An initial investiga-
tion [15] of the pharmacokinetics of
azithromycin both alone and with iver-
mectin and albendazole demonstrated
minimal interaction between azithromycin
and albendazole. However, the ivermectin
AUC0Rt and Cmax were increased by
31% and 27%, respectively. A population
PK model was developed based on the
ivermectin PK data from this study [15] to
further characterize the interaction and
explore the sources of variability between
subjects and across treatments. When the
data were simulated 1,000 times for
18,000 subjects exposed, no single value
came close to a previously established
safety threshold [17].
The results of the PK studies should also
be carefully evaluated and used to inform
the timing of the follow-up visits for safety
assessment.
Pilot Intervention Phase
Prior to implementing MDA in an
endemic area, a pilot study in a limited
number of subjects may be carried out to
compare the standard of care to the
combination therapy. The principal ob-
jective of the pilot study would be to
establish the safety and feasibility of the
combination therapy, and to identify
subgroups and events that may require
special follow-up during the MDA phase.
The design of the pilot phase may
involve cluster randomization, and sample
size requirements may need to be justified
on statistical grounds. Eligibility may be
restricted to consenting residents of en-
demic sites, excluding subjects with special
co-morbidities, children below a specified
height, pregnant women, lactating wom-
en, and/or women who have given birth
within a certain time period (see, e.g., [7]
for general guidelines).
For safety follow-ups, both active and
passive surveillance approaches will need
to be implemented [16]. In particular, as
part of the active case detection effort, a
process should be in place to manage
patients with serious adverse events.
In the Zanzibar study, the pilot trial
involved over 5,000 children and adults at
two sites. In a trachoma/LF study, the
initial trial may consist of an open-label,
community-based, randomized, triple co-
administration design. The study would
enroll eligible children and adults living in
an endemic region, with co-administration
of azithromycin, ivermectin, and albenda-
zole. The trial duration would be 15 days
and may involve two randomly selected
villages: village A (standard care as
control) and village B (triple therapy).
Mass Drug Administration
Phase
Subject Eligibility
In a typical MDA study, all consenting
residents of selected villages in endemic
areas would be eligible for enrollment.
However, depending on the formulation
and safety profile of the drugs, certain
criteria may be used to guide exclusion of
subjects from the study [7]. In a tracho-
ma/LF study protocol, for example, sub-
jects may be excluded for one or more of
the following criteria: subjects who cannot
swallow tablets, subjects who are sick,
pregnant women, and lactating women.
Allocation to Treatment
In general, MDA studies are open-label,
and assignment of eligible subjects to
treatments should occur sequentially as
they are screened for the study at each site.
For proper identification (ID), patients
may be given ID numbers according to
their order of entry into the study.
Safety Surveillance
Both passive and active measures should
be in place to ensure the safety of study
participants and the effective assessment of
adverse events reported during the study
period (see, e.g., [16]).
Passive measures should aim at ensuring
rapid identification of, and provision for,
medical assistance for treatment emergent
signs and symptoms. Health centers with
appropriate drug supplies will need to be
designated at convenient locations. Plan-
ning should also include adequate trans-
portation, for both health care providers
and patients, to ensure a rapid response.
For serious adverse reactions, a referral
system should be established, with referred
patients followed up on a daily basis.
Active measures are essential to assess
and evaluate the nature and rates of
adverse events. Emphasis should be given
to serious adverse events, adverse events
that may be attributable to the combina-
tion therapy, and other adverse events
suggested by the pilot phase. However, all
treated individuals should be interviewed
for occurrences of any side effect using a
standardized questionnaire. Efforts should
also be made to capture adverse events
that may be of interest for special groups,
including the elderly, females of childbear-
ing age, children, and patients with co-
morbid conditions.
When active case detection is not
feasible, which may be the reality in
resource-limited areas, every effort must
be made to utilize existing health infra-
structure to reach patients experiencing
adverse events. Coordination with local
and regional officials may be essential to
ensure rapid communication and response
(see, e.g., [20]).
Subject Withdrawal
Subjects may withdraw from the study
at any time at their own request. In a
single-dose treatment design, this refers to
the situation when a subject does not
return for follow-up evaluation. When
multiple doses are involved, patients may
also be withdrawn at any time at the
discretion of the investigator for safety,
behavioral, or administrative reasons. If a
subject does not return for a scheduled
visit, every effort should be made to
contact the subject and to document
treatment outcome and the reason for
withdrawal.
Adverse Event Reporting
Safety should be assessed for a suffi-
ciently long period of time after drug
administration, depending on the PK and
safety profile of the individual drugs
administered.
An adverse event is defined as any
untoward medical occurrence in patients
who are administered investigational treat-
ment. The events need not necessarily
have a causal relationship with the treat-
ment. Additionally, they may include signs
or symptoms resulting from drug over-
dose, drug withdrawal, drug abuse, drug
misuse, drug interactions, drug dependen-
cy, extravasations, and exposure in utero.
A serious adverse event or serious
adverse drug reaction (SAE), on the other
hand, is defined as any untoward medical
occurrence at any dose that results in
death, is life-threatening (immediate risk of
death), requires inpatient hospitalization
or prolongation of existing hospitalization,
results in persistent or significant disability
and incapacity, or results in a congenital
anomaly or birth defect.
The study protocol should state clearly
the reporting procedure for SAEs to local
and regulatory authorities, consistent with
the local regulations and practice. More
specifically, if an SAE occurs, notification
should be made within 24 hours of
awareness of the event by the investigators.
In particular, if the SAE is fatal or life-
threatening, notification must be made
immediately, irrespective of the extent of
available adverse event information.
For all SAEs, the investigator should
pursue and provide information that will
include a description of the adverse event
www.plosntds.org 2 January 2010 | Volume 4 | Issue 1 | e564in sufficient detail to allow for a complete
medical assessment of the case and
independent determination of possible
causality. Information on other possible
causes of the event, such as concomitant
medications and illnesses, must be provid-
ed. In the case of a subject’s death, a
summary of available autopsy findings
must also be submitted as soon as possible.
The causality assessment includes the
determination of whether there exists a
reasonable possibility that the multiple
administration caused or contributed to
an adverse event, above and beyond that
expected by the individual therapies.
Data Handling and Statistical
Considerations
Data Collection
Simple and convenient data collection
tools such as questionnaires, case report
forms, or, where possible, electronic data
collection devices should be used [21].
The safety data collected should particu-
larly focus on relevant adverse events,
including: serious adverse events, adverse
events attributable to the combination
treatment, and adverse events that may
influence compliance with the combina-
tion therapy.
As part of the overall planning for the
MDA study, it may be worthwhile to
establish data centers at convenient loca-
tions. Data capture may be facilitated by
use of trained personnel or community
volunteers. Use of existing health infra-
structure is advised to facilitate reporting
and assessment of adverse events.
Sample Size Requirement
In MDA studies, the entire population is
normally targeted, and as a result, formal
sample size calculations may not be
required. However, when there is a need
to assess sample size requirements, the unit
of randomization (i.e., cluster) should be
carefully defined, and the sample size
determination and subsequent analysis
and data summarization should take into
account the clustering. Failure to do so
may lead to inappropriate sample sizes
and spurious results.
In cluster randomized studies, which
may be suitable for the pilot phase, the
sample size is a function of estimates of
disease prevalence, the cluster size (m), and
the intra-cluster correlation coefficient
(ICC) or the design effect (Deff). The latter
is also known as variance inflation. Loosely
speaking, ICC measures the association
between pairs drawn from each cluster.
For binary data, the kappa coefficient may
be used instead of ICC [22]. The design
effect is the ratio of the number of subjects
required using cluster randomization to
that required for a design involving simple
randomization. It is related to ICC as
follows:
Deff~1z m{1 ðÞ |ICC
Thus the sample size required for a
cluster randomization may be estimated
by multiplying by the design effect the
number obtained for a simple randomized
trial using standard software or a desk
calculator.
In addition, the ‘‘Rule of Three’’ may be
applied as an aid to assess adequacy of
sample size and to enhance understanding
of findings of no events as part of the active
safety surveillance measures. More specifi-
cally,ifinnsubjects no events occur, then an
approximation to the upper 95% confidence
interval for the true proportion of the event
of interest is 3/n. This approximation is
reliable for most MDA situations. However,
in cluster randomization, the assumption of
independence may not be justified (see, e.g.,
[23–26] for relevant references).
Data Analysis
The analysis strategy for MDA trials
should be estimation rather than hypoth-
esis testing. Such studies usually tend to be
large, giving statistically significant results
even when the results are not clinically
significant. When necessary, 95% confi-
dence intervals may be provided along
with estimates of treatment effects.
It is essential to pre-specify the main
aspects of the analysis strategy either in the
body of the protocol or in a separate analysis
plan, which must be finalized before data
a r er e a d yf o ra n a l y s i s .T h ep l a ns h o u l d
specify at a minimum the primary safety
endpoints, criteria for excluding subjects
from analysis, and all applicable analytical
or data summary methods.
Administrative Considerations
Study Monitoring
To ensure adherence to protocol re-
quirements and maximize data quality, the
study may have a monitoring plan that can
easily be understood and implemented by
the study personnel. The plan may
describe, among other tasks, roles of
personnel responsible for monitoring, the
nature and level of monitoring activities,
and other data quality assurance steps.
Safety Monitoring
When there is further concern about
exposing a large segment of the population
to the combination therapy, the study plan
may also include more targeted safety
monitoring. This may involve establishing
a data and safety monitoring board
(DSMB), consisting of independent ex-
perts. The DSMB periodically reviews and
evaluates the accumulated data, and
makes recommendations concerning the
continuation, modification, or termination
of the trial. In establishing a DSMB for
such studies, particular attention should be
paid to feasibility and logistical challenges.
Operational guidelines for health research
sponsors for the establishment and func-
tioning of DSMBs may be found, e.g., in
[27].
Ethical Considerations
The study protocol should be reviewed
and approved by an institutional review
board (IRB) and ethics committee. For
countries where ethics committees are not
yet available, it may be necessary to use a
non-local committee. In addition, written
and oral informed consent should be
obtained from study participants. An
informed consent by a parent or legal
guardian and assent by the child, as
appropriate, should also be provided prior
to any study-related procedures.
Training of Study Personnel and
Volunteers
Prior to initiation of the study, a
meeting should be held involving key
study personnel to ensure a thorough
and common understanding of the re-
quirements of the protocol. The partici-
pants may include health care profession-
als, opinion leaders, study monitors, and
study sponsors. Discussions should focus
on eligibility criteria, compliance, safety
reporting, and study monitoring. In addi-
tion, it is advisable to have presentations
on basic concepts of clinical trials and
significant aspects of bioethics.
Special Populations
While the general approach in MDA
studies is to enroll all consenting patients
with limited exclusion criteria, the safety
impact in special populations, including
elderly, pediatric patients, and patients
with co-morbid conditions, should also be
given careful consideration. Since the
design of pragmatic studies may not
generally be appropriate to assess safety
and efficacy in subgroups that require
special follow-up and evaluation, other
direct and indirect measures may be taken
to assess the risk–benefit of treatment.
Depending on the subgroup of interest
and disease under consideration, reason-
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logic studies and meta-analysis (see, e.g.,
[28,29]).
Further, in view of the known geo-
graphic overlap between the NTDs and
such major diseases as malaria, HIV/
AIDS, and tuberculosis, treatment strate-
gies eventually may target combination
therapies to include these conditions [30].
Therefore, particular attention must be
paid to safety assessment in the relevant
patient groups.
Discussion
The wide recognition of the benefits of
integrating the control of NTDs has
necessitated the need for an effective
pharmacovigilance framework to mini-
mize the risk to the population in the
affected areas. Given the relatively poor
infrastructure in these resource-limited
regions, careful planning is essential to
gather critical information about the safety
profiles of the combination therapy before
implementing an MDA program. To
ensure a successful outcome, the plan
should take into consideration the enor-
mous challenges, in both execution and
research, and should be based on an
understanding of the local customs and
regular health system.
In this policy platform, we highlighted
key elements of a MDA study, including
PK profiling, trial design, safety data
collection and analysis, and other admin-
istrative issues. It should, however, be
noted that not all aspects of the points
considered may be germane for all situa-
tions. For example, the establishment of
DSMBs or the need for PK profiling may
not be feasible or essential depending on
the diseases under study, the treatments,
or the target population. While the
guidance in this paper is primarily intend-
ed to raise general awareness of design and
logistical issues, any or all of the elements
should be implemented with caution and
a full evaluation of practicality and
relevance.
In addressing issues that are pertinent to
the design, conduct, and analysis of MDA
studies, it is essential to recognize the
features that distinguish such studies from
conventional clinical trials for efficacy
[31]. While the setting for the latter is
typically an ideal condition that permits
reliable determination of treatment effect
size, pragmatic studies for safety are
usually executed under the ‘‘usual condi-
tions.’’ Generally, most consenting adults
in endemic areas are included in pragmat-
ic studies, and treatment is administered
with more flexibility than in conventional
efficacy trials. Unlike efficacy trials in
which a placebo may be used as a
comparator, in pragmatic studies the
control group involves the best available
management strategy. Typically, visits
may be infrequent and informal in
MDA-type studies, with minimal and
targeted data collection. Whereas the
outcome is generally known to be a direct
consequence or surrogate of study drug
effect in conventional efficacy trials, in
pragmatic studies the goal is to assess
safety signals when the drugs are exposed
to a wider population in a real-world
setting. Unlike in conventional efficacy
trials, adherence to protocol by patients or
study personnel is not proactively and
aggressively monitored in pragmatic stud-
ies. It is, therefore, of paramount impor-
tance to have in place the active safety
surveillance measures discussed earlier to
ensure that rare events are not inadver-
tently missed. Further, requirements for
the dissemination of study results for such
studies may not be as clearly defined as in
the case of clinical trials in the developed
world. Therefore, it may be advisable to
incorporate in the study protocol the
strategy for effective communication of
study results.
In most MDA programs, the efficacy of
the individual drugs is well established,
and studies to evaluate the efficacy of the
combination therapy are not often con-
ducted. While PK studies may provide
valuable data about drug interactions, they
generally are not large enough to conclu-
sively establish the absence or existence of
synergy among the drugs involved. Given
the added logistical difficulty of collecting
reliable data on efficacy and other out-
come measures, it may not be feasible to
incorporate non-safety data assessment in
MDA studies. However, as experience is
gained with the conduct of more and more
MDA studies in these resource-con-
strained areas, the plausibility of address-
ing efficacy issues may eventually need to
be tackled.
Acknowledgments
The authors would like to thank the colleagues
at many organizations for their helpful collab-
oration in developing this portion of an MDA
program in West Africa.
References
1. Hotez PJ (2008) Forgotten people and forgotten
diseases: the neglected tropical diseases and their
impact on global health and development.
Washington (D.C.): ASM Press.
2. Molyneux DH (2004) ‘‘Neglected’’ diseases but
unrecognized successes – challenges and oppor-
tunities for infectious disease control. Lancet 364:
380–383.
3. Molyneux DH, Nantulya VM (2004) Linking
disease control programmes in rural Africa: a
pro-poor strategy to reach Abuja targets and
millennium development goals. BMJ 328: 1129–
1132.
4. Lammie PJ, Fenwick A, Utzinger J (2006) A
blueprint for success: integration of neglected
tropical disease control programmes. Trends
Parasitol 22: 313–321.
5. Hopkins DR, Eigege A, Miri ES, Gontor I,
Ogah G, et al. (2002) Lymphatic filariasis
elimination and schistosomiasis control in combi-
nation with onchocerciasis control in Nigeria.
Am J Trop Med Hyg 67: 266–272.
6. Hotez PJ, Ottesen E, Fenwick A, Molyneux D
(2006) The neglected tropical diseases: the ancient
afflictions of stigma and poverty and the prospects
for their control and elimination. Adv Exp Med
Biol 582: 22–33.
7. Hotez PJ, Molyneux DH, Fenwick A, Kumarsan J,
Ehlich Sachs S, et al. (2007) Control of neglected
tropical diseases. N Engl J Med 357: 1018–1027.
8. Horton J, Witt C, Ottesen A, Lazdins JK,
Addiss DJ, et al. (2000) An analysis of the safety
of single dose, two drug regimens used in
programmes to eliminate lymphatic filariasis.
Parasitology 121 (Suppl): S147–S160.
9. Molyneux DH, Hotez PJ, Fenwick A (2005)
‘‘Rapid-impact interventions’’: how a policy of
integrated control for Africa’s neglected tropical
diseases could benefit the poor. PLoS Med 2:
e336. doi:10.1371/journal.pmed.0020336.
10. Hotez PJ, Raff S, Fenwick A, Richards Jr F,
Molyneux DH (2007) Recent progress in inte-
grated neglected tropical disease control. Trends
Parasitol 23(11): 511–514.
11. Fenwick A, Molyneux DH, Nantulya V (2005)
Achieving the Millennium Development Goals.
Lancet 365: 1029–1030.
12. Fenwick A (2006) New initiatives against Africa’s
worms. Trans R Soc Trop Med Hyg 100: 200–207.
1 3 . W o r l dH e a l t hO r g a n i z a t i o n( 2 0 0 9 )Ah u m a nr i g h t s -
based approach to neglected tropical diseases.
Available: http://www.who.int/neglected_diseases/
Human_rights_approach_to_NTD_Eng_ok.pdf.
Accessed 27 October 2009.
14. Brady MA, Hooper PJ, Ottesen EA (2006)
Projected benefits from integrating NTD pro-
grams in sub-Saharan Africa. Trends Parasitol
22: 285–291.
15. Amsden GW, Gregory TV, Michalak CA, Glue P,
Knirsch C (2007) Pharmacokinetics of azithro-
mycin and the combination of ivermectin and
albendazole when administered alone and con-
currently in healthy volunteers. Am J Trop Med
Hyg 76: 1153–1157.
16. Mohammed KA, Haji HJ, Gabrielli AF,
Mubila L, Biswas G, et al. (2008) Triple co-
administration of ivermectin, albendazole and
praziquantel in Zanzibar: a safety study. PLoS
Negl Trop Dis 2: e171. doi:10.1371/journal.
pntd.0000171.
17. Guzzo CA, Furtek CI, Porras AG, Chen C,
Tipping R, et al. (2002) Safety, tolerability and
pharmacokinetics of escalating high doses of
ivermectin in healthy adult subjects. J Cl in
Pharmacol 42: 1122–1133.
18. Olds GR, King C, Hewlett J, Olveda R, Wu G,
et al. (1999) Double-blind, placebo-controlled
study of concurrent administration of albendazole
and praziquantel in schoolchildren with schisto-
somiasis and geohelminths. J Infect Dis 179: 996–
1003.
www.plosntds.org 4 January 2010 | Volume 4 | Issue 1 | e56419. Na-bangchang K, Kietinun S, Pawa KK,
Hanpitakpong W, Na-bangchang C, et al.
(2006) Assessments of pharmacokinetic drug
interactions and tolerability of albendazole,
praziquantel and ivermectin combinations.
Trans R Soc Trop Med Hyg 100: 333–345.
20. Gre ´pin KA, Reich MR (2008) Conceptualizing
integration: a framework for analysis applied to
neglected tropical disease control partnerships.
PLoS Negl Trop Dis 2: e174. doi:10.1371/
journal.pntd.0000174.
21. Sevene E, Mariano A, Mehta U, Machai M,
Dodoo A, et al. (2008) Spontaneous adverse drug
reaction reporting in rural districts of Mozambi-
que. Drug Safety 31: 867–876.
22. Donner A, Birkett N, Buck C (1981) Randomi-
zation by cluster, sample size requirements and
analysis. Am J Epidemiol 114: 906–914.
23. Gail MH (1974) Power computations for design-
ing comparative Poisson trials. Biometrics 30:
231–237.
24. Brown CC, Green SB (1982) Additional power
computations for designing comparative Poisson
trials. Am J Epidemiol 115: 752–758.
25. Eypasch E, Lefering R, Kum CK, Troidl H
(1995) Probability of adverse events that have not
yet occurred: a statistical reminder. BMJ 311:
619–620.
26. Hanley JA, Lippman-Hand A (1983) If nothing
goes wrong, is everything all right? Interpreting
zero numerators. JAMA 249: 1743–1745.
27. UNDP/World Bank/WHO Special Programme
for Research and Training in Tropical Diseases
(TDR) (2005) Operational guidelines for the
establishment and functioning of data and safety
monitoring boards. Available: http://www.sidcer.
org/new_web/pdf/2006/operat_guidelines.pdf.
Accessed 27 October 2009.
28. Pouillot R, Matias G, Wondje CM, Portaels F,
Valin N, et al. (2007) Risk factors for Buruli ulcer:
a case control study in Cameroon. PLoS Negl
Trop Dis 1: e101. doi:10.1371/journal.pntd.
0000101.
29. Kim DH, Chung HJ, Bleys J, Ghohestani RF
(2009) Is paromomycin an effective and safe
treatment against cutaneous leishmaniasis? A
meta-analysis of 14 randomized controlled trials.
PLoS Negl Trop Dis 3: e381. doi:10.1371/
journal.pntd.0000381.
30. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E,
Ehrlich Sachs S, et al. (2006) Incorporating a
rapid-impact package for neglected tropical
diseases with programs for HIV/AIDS, tubercu-
losis, and malaria. PLoS Med 3: e102.
doi:10.1371/journal.pmed.0030102.
3 1 .T h o r p eK E ,Z w a r e n s t e i nM ,O x m a nA D ,
Treweek S, Furberg CD, et al. (2009) A
pragmatic—explanatory continuum indicator
summary (PRECIS): a tool to help trial designers.
J Clin Epidemiol 62: 464–475.
www.plosntds.org 5 January 2010 | Volume 4 | Issue 1 | e564